January 14th, 2015
Ticagrelor Improves Outcomes After Myocardial Infarction
Larry Husten, PHD
For the first time, a very large trial has shown that dual antiplatelet therapy (DAPT) improves cardiovascular outcomes when given to patients 1 to 3 years after a myocardial infarction. Because DAPT has been shown previously to reduce the high risk of recurrent events for up to a year following an MI, it is considered to be standard […]
January 27th, 2011
End of an Era: Eugene Braunwald Steps Down, Marc Sabatine Assumes Chair of TIMI Group
Larry Husten, PHD
Marc Sabatine has replaced Eugene Braunwald as the chairman of the TIMI study group. Braunwald, who has been the dominant figure in cardiology for many decades, is 81. Sabatine was appointed Vice Chairman of the TIMI group last summer and he assumed the chairman’s role on January 1. Braunwald is not retiring and will continue to […]
January 13th, 2011
Merck’s Thrombin Receptor Antagonist Suffers Major Setback
Larry Husten, PHD
Merck’s thrombin receptor antagonist, vorapaxar, has suffered a major setback in its clinical trial program. In one trial, TRACER, the study drug is being discontinued and the trial will be closed out. The second trial, TRA-2P TIMI 50, is being curtailed but not stopped. The actions were based on recommendations from the combined Data and […]
NEJM Journal Watch — Recent Cardiology Articles- Transcatheter Valve Replacement for Severe Tricuspid Regurgitation
- Time in Blood Pressure Target Range and Outcomes in Hypertension: Real-World Data
- When to Start Anticoagulation After Ischemic Stroke in Patients with Atrial Fibrillation
- Aortic-Valve Replacement vs. Clinical Surveillance for Asymptomatic Severe Aortic Stenosis
- Secondary Hypertension in Young Adults